Subjects n | 55 | 55 | |
Daily ICS use# | | | |
Dose μg | | | |
Mean±sd | 176.0±143.0 | 302.5±84.8 | −126.5 (95% CI −171.0– −81.9)¶ |
Median (IQR) | 164.3 (74.0–251.7) | 328.3 (245.8–364.0) | |
Range (minimum–maximum) | 6.7–682.5 | 26.8–458.1 | |
Mean adherence % | | 76 | |
Actuations | | | |
Mean±sd | 0.9±0.7 | 1.5±0.4 | |
Median (IQR) | 0.8 (0.4–1.3) | 1.6 (1.2–1.8) | |
Range (minimum–maximum) | 0.0–3.4 | 0.1–2.3 | |
Days of no ICS use | | | 119 (95% CI 90–191)¶ |
Mean±sd | 182.0±109.4 | 45.9±64.6 | |
Median (IQR) | 156 (95–284) | 22 (6–70) | |
Range (minimum–maximum) | 0–352 | 0–327 | |
Weeks of no ICS use | | | 3 (95% CI 1–8)¶ |
Mean±sd | 12.6±15.4 | 1.8±6.6 | |
Median (IQR) | 4 (0–24) | 0 (0–1) | |
Range (minimum–maximum) | 0–48 | 0–38 | |
2-week periods of no ICS use | | | 0 (95% CI 0–2)¶ |
Mean±sd | 4.6±6.8 | 0.7±2.8 | |
Median (IQR) | 0 (0–7) | 0 (0–0) | |
Range (minimum–maximum) | 0–23 | 0–17 | |
Longest period of no ICS use days | | | |
Mean±sd | 40.3±59.9 | 8.7±19.4 | |
Median (IQR) | 12 (5–48) | 3 (1–8) | |
Range (minimum–maximum) | 0–260 | 0–129 | |
Maximum ICS actuations in a single day | | | |
Mean±sd | 6.0±2.9 | 4.3±2.0 | |
Median (IQR) | 5 (4–8) | 4 (3–5) | |
Range (minimum–maximum) | 1–13 | 2–14 | |
Days ≥2 ICS actuations | | | |
Total days across all participants in the whole study n | 4175 | 10 672 | |
Mean±sd per participant | 75.9±72.8 | 194.0±89.7 | |
Median (IQR) per participant | 48 (15–114) | 204 (122.5–273) | |
Range (minimum–maximum) | 0–329 | 14–333 | |
Days ≥4 ICS actuations | | | |
Total days across all participants in the whole study n | 675 | 172 | |
Mean±sd per participant | 12.3±26.0 | 3.1±7.7 | |
Median (IQR) per participant | 4 (1–10) | 1 (0–3) | |
Range (minimum–maximum) | 0–153 | 0–52 | |
Days ≥6 ICS actuations | | | |
Total days across all participants in the whole study n | 176 | 23 | |
Mean±sd per participant | 3.2±8.2 | 0.4±1.8 | |
Median (IQR) per participant | 0 (0–2) | 0 (0–0) | |
Range (minimum–maximum) | 0–39 | 0–12 | |